Research Paper Volume 16, Issue 5 pp 4518—4540
Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy
Figure 10. Immunotherapy response prediction. (A) Submap analysis manifested that low risk group could be more sensitive to the PD-1 inhibitor (Bonferroni-corrected P = 0.07), and high risk group are insensitive to anti-CTLA-4 therapy (Bonferroni corrected P = 0.039); (B) Kaplan–Meier survival analysis of risk model in Hugo et al melanoma study (accession number: GSE78220); (C) Kaplan–Meier survival analysis of risk model in Riaz et al melanoma study (accession number: GSE91061); (D) The risk score distribution of anti-PD-1 therapy between response and non-response in GSE78220; (E) The risk score distribution of anti-PD-1 therapy between response and non-response in GSE91061; (F) Gene set enrichment analysis (GSEA) of high vs low risk scores groups in cancer hallmark pathways.